To test this hypothesis, we inhibited IL-17A expression at tumor sites by intratumoral injection of an adenovirus vector expressing IL-17A siRNA (Ad-si-IL-17) in WT mice and examined the effects on tumor progression. This evidence concerns the gene IL17A and neoplasm.